Cancer pain and its impact on diagnosis, survival and quality of life

Cancer pain significantly affects the diagnosis, quality of life and survival of patients with cancer. During the past decade, preclinical and clinical data has begun to provide insight into the mechanisms that drive and mask cancer pain and the mechanisms by which anti-neoplastic agents induce peripheral neuropathy. Developing a mechanism-based understanding and mechanism-based therapies to treat cancer-associated pain and sensory neuropathy, and incorporating these into mainstream cancer research and therapy, will be crucial to improving the quality of life and survival of patients with cancer.

[1]  Richard Carter,et al.  Breakthrough , 1966 .

[2]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[3]  J. Jacobs,et al.  Vascular permeability and neurotoxicity. , 1978, Environmental health perspectives.

[4]  A I Basbaum,et al.  Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. , 1984, Annual review of neuroscience.

[5]  J. Bonica,et al.  Management of cancer pain. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[6]  K. Johnson.  An Update. , 1984, Journal of food protection.

[7]  L. King,et al.  Role of epidermal growth factor in carcinogenesis. , 1986, Cancer research.

[8]  T. Ness,et al.  Characterization of neuronal responses to noxious visceral and somatic stimuli in the medial lumbosacral spinal cord of the rat. , 1987, Journal of neurophysiology.

[9]  H. Thoenen,et al.  Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection , 1987, The Journal of cell biology.

[10]  L. Terenius,et al.  Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. , 1988, Journal of the autonomic nervous system.

[11]  M. Schultzberg,et al.  Substance P- and CGRP-immunoreactive nerves in bone , 1988, Peptides.

[12]  P. Anderson,et al.  Satellite cells surrounding axotomised rat dorsal root ganglion cells increase expression of a GFAP-like protein , 1989, Neuroscience Letters.

[13]  W. Tetzlaff,et al.  Influence of nerve growth factor on neurofilament gene expression in mature primary sensory neurons , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  J. Griffiths.  Are cancer cells acidic? , 1991, British Journal of Cancer.

[15]  O. S. Nielsen,et al.  Bone metastases: pathophysiology and management policy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Growth factors and their receptors in metastasis. , 1991, Seminars in cancer biology.

[17]  C. Stein,et al.  Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: Evidence for a regulatory function of nerve growth factor in vivo , 1992, Neuroscience.

[18]  Silverman Bj.  Platelet-derived growth factor in human malignancy. , 1992 .

[19]  B. Rifkin.  Biology and Physiology of the Osteoclast , 1992 .

[20]  Platelet-derived growth factor in human malignancy. , 1992, BioFactors.

[21]  C. Stein,et al.  Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: Evidence for a regulatory function of nerve growth factor in vivo , 1992, Neuropeptides.

[22]  A. Dray,et al.  Sensitization of peripheral afferent fibres in the in vitro neonatal rat spinal cord-tail by bradykinin and prostaglandins , 1993, Neuroscience.

[23]  S. McMahon,et al.  Immunocytochemical Localization of trkA Receptors in Chemically Identified Subgroups of Adult Rat Sensory Neurons , 1995, The European journal of neuroscience.

[24]  C. Galasko,et al.  Diagnosis of skeletal metastases and assessment of response to treatment. , 1995, Clinical orthopaedics and related research.

[25]  B F Boyce,et al.  Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. , 1995, Cancer research.

[26]  Steven F. Maier,et al.  Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states , 1995, Pain.

[27]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[28]  J. Heimans,et al.  Paclitaxel-induced neuropathy. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Vasko,et al.  Prostaglandin-induced neuropeptide release from spinal cord. , 1995, Progress in brain research.

[30]  H. Thaler,et al.  Pain and depression in patients with newly diagnosed pancreas cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Choy,et al.  Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. , 1995, Journal of the National Cancer Institute.

[32]  K. Foley.  Misconceptions and controversies regarding the use of opioids in cancer pain. , 1995, Anti-cancer drugs.

[33]  Tonic endogenous opioid inhibition of visceral noxious information in rabbits. , 1996, Gastroenterology.

[34]  A. Malhotra,et al.  Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[35]  John P. Bilezikian,et al.  Principles of Bone Biology , 1996 .

[36]  H. Ozawa,et al.  Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor. , 1996, Bone.

[37]  S. Felten,et al.  Noradrenergic and peptidergic innervation of the mouse femur bone marrow. , 1996, Acta histochemica.

[38]  J. Compston,et al.  Principles of Bone Biology , 1997 .

[39]  S. Mercadante.  Malignant bone pain: pathophysiology and treatment , 1996, Pain.

[40]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[41]  G. Cavaletti,et al.  Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. , 1997, Neurotoxicology.

[42]  A. Andrén-sandberg,et al.  Prospective evaluation of pain in exocrine pancreatic cancer. , 1997, Digestion.

[43]  M. Lazdunski,et al.  The Acid-sensitive Ionic Channel Subunit ASIC and the Mammalian Degenerin MDEG Form a Heteromultimeric H+-gated Na+ Channel with Novel Properties* , 1997, The Journal of Biological Chemistry.

[44]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[45]  Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  G. Hans,et al.  Behavioral signs of acute pain produced by application of endothelin‐1 to rat sciatic nerve , 1998, Neuroreport.

[47]  E. Venkatraman,et al.  Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[49]  P. Distefano,et al.  Physiological characterization of taxol‐induced large‐fiber sensory neuropathy in the rat , 1998, Annals of neurology.

[50]  B. Weber,et al.  Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma A multicenter GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study , 1998 .

[51]  X. Ortiz-González,et al.  An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats , 1998, Neuroreport.

[52]  A. Basbaum,et al.  The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.

[53]  S. Mercadante,et al.  Breakthrough pain in cancer patients: pathophysiology and treatment. , 1998, Cancer treatment reviews.

[54]  C. R. Bagnell,et al.  Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[55]  F. Fulfaro,et al.  The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials , 1998, Pain.

[56]  S. Adami,et al.  New Bisphosphonates in the Treatment of Bone Diseases , 1999, Drugs & aging.

[57]  C. Theiss,et al.  Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro , 2000, Cell and Tissue Research.

[58]  F. Sinicrope,et al.  Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. , 1999, Cancer research.

[59]  S. Mercadante.  Problems of long-term spinal opioid treatment in advanced cancer patients , 1999, Pain.

[60]  G. Mundy,et al.  Bone remodeling and its disorders , 1999 .

[61]  M. Weber,et al.  Documentation of severe pain, opioid doses, and opioid-related side effects in outpatients with cancer: a retrospective study. , 1999, Journal of pain and symptom management.

[62]  Paul Jacobsen,et al.  Breakthrough pain: characteristics and impact in patients with cancer pain , 1999, Pain.

[63]  J. Ross,et al.  Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. , 1999, Nutrition and cancer.

[64]  F Leonardi,et al.  Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma. , 1999, American journal of clinical oncology.

[65]  M. Kawaja,et al.  Absence of the p75 Neurotrophin Receptor Alters the Pattern of Sympathosensory Sprouting in the Trigeminal Ganglia of Mice Overexpressing Nerve Growth Factor , 1999, The Journal of Neuroscience.

[66]  I. Zagon,et al.  Elevated Levels of Opioid Growth Factor in the Plasma of Patients with Pancreatic Cancer , 2000, Pancreas.

[67]  M. Zucchetti,et al.  Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. , 2000, Neurotoxicology.

[68]  A. Lipton,et al.  Oral bisphosphonates , 2000, Cancer.

[69]  N. Cherny.  New strategies in opioid therapy for cancer pain. , 2000, The Journal of oncology management : the official journal of the American College of Oncology Administrators.

[70]  P. Yarnold,et al.  IL-1β AND TNF-α IN PROSTATIC SECRETIONS ARE INDICATORS IN THE EVALUATION OF MEN WITH CHRONIC PROSTATITIS , 2000 .

[71]  P. Boyle,et al.  Pathophysiology and Treatment , 2000 .

[72]  H. Gould,et al.  A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain , 2000, Brain Research.

[73]  E. Mccleskey,et al.  Chemical mediators of pain due to tissue damage and ischemia. , 2000, Progress in brain research.

[74]  辻野 宏明.  Activating transcription factor 3 (ATF 3) induction by axotomy in sensory and motoneurons : a novel neuronal marker of nerve injury , 2000 .

[75]  S. Perkins,et al.  Review of Cellular Mechanisms of Tumor Osteolysis , 2000, Clinical orthopaedics and related research.

[76]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[77]  M. Kress,et al.  Involvement of the Proinflammatory Cytokines Tumor Necrosis Factor-α, IL-1β, and IL-6 But Not IL-8 in the Development of Heat Hyperalgesia: Effects on Heat-Evoked Calcitonin Gene-Related Peptide Release from Rat Skin , 2000, The Journal of Neuroscience.

[78]  J. Mönkkönen,et al.  Cellular and molecular mechanisms of action of bisphosphonates , 2000, Cancer.

[79]  T. Hambley,et al.  Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs , 2000, British Journal of Cancer.

[80]  J. Body.  Tumor bone diseases and osteoporosis in cancer patients : pathophysiology, diagnosis, and therapy , 2000 .

[81]  J. Nelson,et al.  The role of endothelin‐1 and endothelin receptor antagonists in prostate cancer , 2000, BJU international.

[82]  U. Adler.  Bone Diseases , 2000, Springer Berlin Heidelberg.

[83]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[84]  Atsushi Tokunaga,et al.  Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury , 2000, Molecular and Cellular Neuroscience.

[85]  P. Mantyh,et al.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.

[86]  A I Basbaum,et al.  Impaired nociception and pain sensation in mice lacking the capsaicin receptor. , 2000, Science.

[87]  K. Eguchi,et al.  Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. , 2000, Neurotoxicology.

[88]  S. Dey,et al.  Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.

[89]  Qingyuan Yang,et al.  Increased cyclooxygenase‐2 (cox‐2) expression and activity in a murine model of metastatic breast cancer , 2001, International journal of cancer.

[90]  R. Yezierski,et al.  The role of neuroinflammation and neuroimmune activation in persistent pain , 2001, Pain.

[91]  R. Couture,et al.  Kinin receptors in pain and inflammation. , 2001, European journal of pharmacology.

[92]  R E Coleman,et al.  Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases , 2001, Cancer.

[93]  J. Lotz,et al.  High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). , 2001, European journal of cancer.

[94]  P. Mantyh,et al.  Expression and Localization of Endothelin Receptors: Implications for the Involvement of Peripheral Glia in Nociception , 2001, The Journal of Neuroscience.

[95]  Differential regulation of P2X3 mRNA expression by peripheral nerve injury in intact and injured neurons in the rat sensory ganglia , 2001 .

[96]  E. Kalso,et al.  Morphine and alternative opioids in cancer pain: the EAPC recommendations , 2001, British Journal of Cancer.

[97]  L. Radbruch,et al.  Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology , 2001, Pain.

[98]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[99]  P. Mantyh,et al.  Osteoprotegerin diminishes advanced bone cancer pain. , 2001, Cancer research.

[100]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[101]  A. Basbaum,et al.  Molecular mechanisms of nociception , 2001, Nature.

[102]  S. McMahon,et al.  Nerve growth factor induces P2X3 expression in sensory neurons , 2001, Journal of neurochemistry.

[103]  G. Cavaletti,et al.  Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. , 2001, European journal of cancer.

[104]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[105]  G. Davar.  Endothelin-1 and metastatic cancer pain. , 2001, Pain medicine.

[106]  P. Mantyh.  A mechanism based understanding of cancer pain , 2002, Pain.

[107]  J. Nelson,et al.  Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Martin Koltzenburg,et al.  Molecular mechanisms of cancer pain , 2002, Nature Reviews Cancer.

[109]  G Pelosi,et al.  High-dose chemotherapy in small-cell lung cancer. , 2002, Anticancer research.

[110]  P. Mantyh,et al.  Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. , 2002, Cancer research.

[111]  P. Dobrzanski,et al.  The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[112]  C. Woolf,et al.  p38 MAPK Activation by NGF in Primary Sensory Neurons after Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia , 2002, Neuron.

[113]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[114]  G. Gebhart,et al.  Chronic pain and medullary descending facilitation , 2002, Trends in Neurosciences.

[115]  R. Dubner,et al.  Descending modulation in persistent pain: an update , 2002, Pain.

[116]  D. Yee,et al.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. , 2002, Cancer research.

[117]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors☆ , 2002 .

[118]  E. McLachlan,et al.  Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat , 2002, Neuroscience.

[119]  I. Zagon,et al.  The biology of the opioid growth factor receptor (OGFr) , 2002, Brain Research Reviews.

[120]  P. Franzone,et al.  Considerations on early diagnosis of carcinoma of the pancreas. , 2003, Hepato-gastroenterology.

[121]  C. Gentry,et al.  Regulation and function of spinal and peripheral neuronal B1 bradykinin receptors in inflammatory mechanical hyperalgesia , 2003, Pain.

[122]  J. Stewart.  Bradykinin antagonists as anti-cancer agents. , 2003, Current pharmaceutical design.

[123]  S. Fenwick,et al.  The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. , 2003, Gastroenterology.

[124]  J. Nelson,et al.  The endothelin axis: emerging role in cancer , 2003, Nature Reviews Cancer.

[125]  Atsushi Tokunaga,et al.  Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats , 2003, Pain.

[126]  B. Stewart,et al.  World Cancer Report , 2003 .

[127]  J. Redondo,et al.  Cyclooxygenase-2: a therapeutic target in angiogenesis. , 2003, Trends in molecular medicine.

[128]  A. Grothey.  Oxaliplatin-safety profile: neurotoxicity. , 2003, Seminars in oncology.

[129]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.

[130]  J. Heimans,et al.  Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer , 2003, Journal of Neuro-Oncology.

[131]  A. Blomqvist,et al.  Rat brain vascular distribution of interleukin‐1 type‐1 receptor immunoreactivity: Relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli , 2004, The Journal of comparative neurology.

[132]  N. Davies,et al.  COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. , 2004, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[133]  Michael A. Kuskowski,et al.  Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis , 2004, Pain.

[134]  Y. Olsson,et al.  Vascular permeability of spinal nerve roots , 1990, Acta Neuropathologica.

[135]  P. Dougherty,et al.  Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients , 2004, Pain.

[136]  G. Y. Wong,et al.  Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. , 2004, JAMA.

[137]  S. Wadler,et al.  Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy , 2004, Investigational New Drugs.

[138]  D. Tripathy,et al.  Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. , 2004, Clinical therapeutics.

[139]  H. Fields.  State-dependent opioid control of pain , 2004, Nature Reviews Neuroscience.

[140]  G. Gebhart,et al.  Descending modulation of pain , 2004, Neuroscience & Biobehavioral Reviews.

[141]  P. Mantyh,et al.  Endothelin and the tumorigenic component of bone cancer pain , 2004, Neuroscience.

[142]  P. Mantyh,et al.  Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model. , 2005, The journal of pain : official journal of the American Pain Society.

[143]  V. Roggli,et al.  Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. , 2005, Archives of pathology & laboratory medicine.

[144]  N. Carruthers,et al.  Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain , 2005, The Journal of Neuroscience.

[145]  P. Dennis,et al.  An overview of lung cancer genomics and proteomics. , 2005, American journal of respiratory cell and molecular biology.

[146]  G. Nicolini,et al.  Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. , 2005, European journal of cancer.

[147]  Thomas J. Smith,et al.  Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. , 2005, Journal of palliative medicine.

[148]  P. Mantyh,et al.  Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain , 2005, Experimental Neurology.

[149]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[150]  G. Y. Wong,et al.  Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression , 2005, Pain.

[151]  P. Mantyh,et al.  Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization , 2005, Pain.

[152]  R. Treede,et al.  Human brain mechanisms of pain perception and regulation in health and disease , 2005, European journal of pain.

[153]  P. Mantyh,et al.  A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. , 2005, Cancer research.

[154]  P. Mantyh,et al.  Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. , 2006, Gastroenterology.

[155]  S. Monfardini,et al.  Oxaliplatin-related neurotoxicity: how and why? , 2006, Critical reviews in oncology/hematology.

[156]  Alex Sparreboom,et al.  Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. , 2006, European journal of cancer.

[157]  P. Mantyh,et al.  A quantitative analysis of the sensory and sympathetic innervation of the mouse pancreas , 2006, Neuroscience.

[158]  P. Mantyh,et al.  Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat , 2006, Neuroscience Letters.

[159]  M. Lingen,et al.  Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. , 2006, Microvascular research.

[160]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[161]  G. Y. Wong,et al.  Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells , 2007, Experimental Neurology.

[162]  M. Stillman,et al.  Chemotherapy-induced peripheral neuropathy. , 2005, Oncology nursing forum.